New Year, New Moat Ratings for These Stocks
Competitive advantages improved for one health-care firm, while a spin-off at another narrowed its moat, says Morningstar's Paul Larson in his discussion on recent moat-rating upgrades and downgrades.
Editor's Note: Since the filming of this video, Morningstar equity analyst Matthew Coffina was named editor of Morningstar StockInvestor.
Jeremy Glaser: For Morningstar, I'm Jeremy Glaser. We spend a lot of time here talking about economic moats, or long-term competitive advantages. I'm here with Paul Larson. He is the editor of Morningstar StockInvestor. He is our chief equities strategist, and he is also in charge of our economic moat research. We are going to look at a few new firms that have been recently given the wide-moat rating and a few that have lost it.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.